QIAGEN has received FDA clearance for the clinical use of its QIAstat-Dx Respiratory Panel Plus syndromic test, a diagnostic tool designed for diagnosing upper respiratory infections. It was previously authorized under a US FDA Emergency Use Authorization (EUA) as the QIAstat-Dx Respiratory SARS-CoV-2 Panel.
The QIAstat-Dx Respiratory Panel Plus allows the detection of 21 viral and bacterial targets using real-time PCR technology. The product is claimed to provide results within an hour, including hands-on time up to one minute, viewing cycle threshold (Ct) values, and amplification curves to provide healthcare professionals with additional clinical information. QIAGEN is working on expanding its QIAstat-Dx portfolio in the US with a gastrointestinal panel under FDA review and a meningitis/encephalitis panel in development.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.